CLDX · Celldex Therapeutics, Inc.
$35.28
-0.20% last session
End-of-day data · updated 2026-07-28
Market cap
$3B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-8.0
Dividend yield
—
Beta
0.90
Avg volume
1M
Employees
0K
2D change
—
5D change
0.65%
10D change
0.85%
30D change
1.11%
60D change
13.43%
MTD change
-3.07%
YTD change
31.26%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — CLDX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-22
Latest call per bank · past 12 months
Wells Fargo
Overweight$48.00
+36.1% vs priceMorgan Stanley
Overweight$40.00
+13.4% vs priceUBS
Buy$45.00
+27.6% vs priceBarclays
Overweight$48.00
+36.1% vs priceGoldman Sachs
Neutral$34.00
-3.6% vs priceCitigroup
Buy$48.00
+36.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-22 | Wells Fargo | Maintains | Overweight | $54.00 → $48.00 |
| 2026-07-22 | Morgan Stanley | Maintains | Overweight | $44.00 → $40.00 |
| 2026-07-22 | Cantor Fitzgerald | Maintains | Overweight | $67.00 → $61.00 |
| 2026-07-22 | Canaccord Genuity | Maintains | Buy | $62.00 → $60.00 |
| 2026-07-20 | Guggenheim | Maintains | Buy | $90.00 → $100 |
| 2026-06-15 | HC Wainwright & Co. | Reiterates | Buy | $42.00 |
| 2026-06-10 | UBS | Maintains | Buy | $38.00 → $45.00 |
| 2026-05-13 | Wells Fargo | Maintains | Overweight | $38.00 → $54.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 50 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 5.9% above the 50-day MA ($33.61).
- Price vs 200-day MA: Trading 20.8% above the 200-day MA ($29.45).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.48) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($20.01) and high ($39.93).
CLDX Price Chart
Loading chart for CLDX…
Fundamentals
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.